全球子宮頸抹片/人類乳突病毒(HPV)檢查市場:成長機會及策略 是由出版商Venture Planning Group在2011年12月所出版的。
這份英文市場調查報告書價格從美金3850起跳。
本報告提供全球主要國家(美國、英國、德國、法國、義大利、西班牙、日本)的子宮頸抹片檢查及人類乳突病毒(HPV)檢查市場相關分析，彙整診斷技術的最新趨勢，及今後5∼10年的各國的市場趨勢(檢查數量、診斷收益等)，今後的市場發展的策略和障礙，各企業簡介等資訊，為您概述為以下內容。
第1章 簡介
第2章 全球市場及技術概要
- 子宮頸抹片/人類乳突病毒(HPV)檢查:臨床的意義和研究的實際狀態
- 診斷設備的檢討和市場需求(全23種)
- 現狀/新的診斷技術
- 單株抗體、多株抗體
- 免疫分析
- 分子診斷
- 生物晶片、微陣列
- 染色體分析
- 微電腦、自動化
- 人工智能
- 流式細胞技術
- 生物感應器
- 競爭、技術互補
- 電腦斷層掃描(電腦斷層攝影)
- 核磁共振攝影(核磁共振影像)
- NMR(核磁共振法)
- PET(陽電子斷層法)
- 光電分光學
- 個別檢查
第3章 法國市場:各部門的檢查數量、診斷收益預測
第4章 德國市場:各部門的檢查數量、診斷收益預測
第5章 義大利市場:各部門的檢查數量、診斷收益預測
第6章 日本市場:各部門的檢查數量、診斷收益預測
第7章 西班牙市場:各部門的檢查數量、診斷收益預測
第8章 英國市場:各部門的檢查數量、診斷收益預測
第9章 美國市場:各部門的檢查數量、診斷收益預測
第10章 分散式檢查產品的設計標準
第11章 替代性的市場普及策略
- 內部開發
- 合資企業協定
- 與大學的契約
- 分散檢查市場流通策略
- 行銷的方法
- 產品的複雜性
- 客戶的偏好
- 現有的供應商
- 新加入廠商供應商
- 主要種類的流通業者
- 市場分類
第12章 加入市場的潛在障礙與風險
- 市場的成熟度
- 成本控制
- 競爭
- 技術的限制
- 專利保護
- 法規的限制
- 分散檢查市場課題
第13章 競爭企業分析
- Abbott
- AdnaGen
- Ambrilia Biopharma
- AMDL
- Beckman Coulter
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CanAG Diagnostics
- CeMines
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- 榮研化學
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- 富士Rebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- J&J Diagnostics
- Kreatech
- Kyowa Medex
- Mackay Life Sciences
- Matritech
- Myriad Genetics
- OncoLab
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Veridex
- 和光純藥
- Wallac
- Zila
圖表一覽
Abstract
Description
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment.
The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Contains: 243 pages and 7 tables.
Table of Contents
I. Introduction
II. Worldwide Market and Technology Overview
- A. PAP Smear/HPV: Clinical Significance and Laboratory Practices
- B. Instrumentation Review And Market Needs
- 1. Abbott AxSYM
- 2. Abbott IMx
- 3. Anagen AN2000/AuraFlex
- 4. Beckman Coulter Access
- 5. BioChem Pharma SR1
- 6. bioMerieux Vidas Series
- 7. Biotrol Systems 7000
- 8. J&J Diagnostics/Amersham Amerlite
- 9. J&J Diagnostics Vitros ECI
- 10. Olympus PK Series
- 11. Roche Cobas Core
- 12. Roche Elecsys
- 13. Roche ES 22
- 14. Roche ES 33
- 15. Roche ES 300/300 AL
- 16. Siemens ACS: 180
- 17. Siemens ACS: Centaur
- 18. Siemens ELISA Processor II/III
- 19. Siemens Immuno 1
- 20. Siemens/Opus/Plus/Magnum
- 21. Siemens Stratus
- 22. Tosoh AIA Series
- 23. Wallac/Pharmacia Delfia
- C. Current and Emerging Technologies
- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- a. Technological Principle
- b. Radioimmunoassay (RIA)
- c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
- e. Luminescence
- Chemiluminescence
- Bioluminescence
- 3. Molecular Diagnostics
- a. Technology Overview
- b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
- 4. Biochips/Microarrays
- 5. Chromosome Analysis
- a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- 6. Microcomputers and Automation
- 7. Artificial Intelligence
- 8. Flow Cytometry
- 9. Biosensors
- D. Competing/Complementing Technologies
- 1. CT
- 2. MRI
- 3. NMR
- 4. PET
- 5.Photonics Spectroscopy
- E. Personal Testing
III. France: Test Volume and Diagnostics Sales Forecast by Market Segment
IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment
V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment
VI. Japan: Test Volume and Diagnostics Sales Forecast by Market Segment
VII. Spain: Test Volume and Diagnostics Sales Forecast by Market Segment
VIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market Segment
IX. U.S.A.: Test Volume and Diagnostics Sales Forecast by Market Segment
X. Design Criteria for Decentralized Testing Products
XI. Alternative Market Penetration Strategies
- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
- 1. Marketing Approaches
- 2. Product Complexity
- 3. Customer Preference
- 4. Established Suppliers
- 5. Emerging Suppliers
- 6. Major Types of Distributors
- 7. Market Segmentation Factor
XII. Potential Market Entry Barriers and Risks
- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges
XIII. Competitive Profiles
- Abbott
- AdnaGen
- Ambrilia Biopharma
- AMDL
- Beckman Coulter
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CanAG Diagnostics
- CeMines
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- J&J Diagnostics
- Kreatech
- Kyowa Medex
- Mackay Life Sciences
- Matritech
- Myriad Genetics
- OncoLab
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac
- Zila
List of Tables
- Major Companies Developing or Marketing PAP Smear/HPV Tests
- France
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
- Germany
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
- Italy
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
- Japan
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
- Spain
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
- U.K.
- PAP Smear Test Volume and Diagnostics Sales by Market Segment
